Osteosarcoma: better treatment through better trial design

Affiliations

Comment

Robert S Benjamin. Lancet Oncol. 2015 Jan.

. 2015 Jan;16(1):12-3.

doi: 10.1016/S1470-2045(14)71186-6. Epub 2014 Dec 29.

¹ Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Centre, Houston, TX, USA.

No abstract available

Comment on

Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial.
Grignani G, Palmerini E, Ferraresi V, D'Ambrosio L, Bertulli R, Asaftei SD, Tamburini A, Pignochino Y, Sangiolo D, Marchesi E, Capozzi F, Biagini R, Gambarotti M, Fagioli F, Casali PG, Picci P, Ferrari S, Aglietta M; Italian Sarcoma Group. Grignani G, et al. Lancet Oncol. 2015 Jan;16(1):98-107. doi: 10.1016/S1470-2045(14)71136-2. Epub 2014 Dec 11. Lancet Oncol. 2015. PMID: 25498219 Clinical Trial.